Cellectar Biosciences shares surge 13.27% after-hours after outlining 2026 regulatory roadmap and securing $15.2M in funding.

Cellectar surged 13.27% in after-hours trading following the announcement of a detailed operational roadmap for 2026, including a planned conditional marketing authorization submission for its lead candidate, Iopofosine I-131, to the EMA in Q3 2026 and initiation of a Phase 1b trial for CLR 125 by Q1 2026. The company also highlighted a $15.2 million capital raise to advance its Phospholipid Drug Conjugate platform, alongside favorable regulatory momentum, including FDA Breakthrough Therapy designation for Iopofosine I-131. These developments, coupled with a projected $15.5 billion growth in the radio-conjugate drug sector by 2035, reinforced investor confidence in Cellectar’s near-term execution risks and long-term therapeutic pipeline.